Prolonged survival of patients with non-small-cell lung cancer with leptomeningeal carcinomatosis in the modern treatment era

Clinical Lung Cancer

Volumn 15, Issue 3, 2014, Pages 202-206

  Riess, Jonathan W ^a,c   Nagpal, Seema ^a   Iv, Michael ^a   Zeineh, Michael ^a   Gubens, Matthew A ^b   Ramchandran, Kavitha ^a   Neal, Joel W ^a   Wakelee, Heather A ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; CNS disease; Leptomeningeal carcinomatosis; NSCLC; Targeted therapy

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GADOLINIUM; GEFITINIB; K RAS PROTEIN; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; GADOLINIUM PENTETATE; GLUTAMIC ACID DERIVATIVE; GUANINE; MONOCLONAL ANTIBODY; PROTEIN KINASE INHIBITOR;

ADULT; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DATA BASE; DEATH; DISEASE COURSE; FEMALE; GENE MUTATION; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; MEDICAL RECORD; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; RETROSPECTIVE STUDY; SYSTEMIC THERAPY; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; CARCINOMA, NON-SMALL-CELL LUNG; DIAGNOSTIC USE; LUNG NEOPLASMS; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; PATHOLOGY; PROCEDURES; PROGNOSIS; SECONDARY; SURVIVAL;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CONTRAST MEDIA; FEMALE; GADOLINIUM; GADOLINIUM DTPA; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MENINGEAL CARCINOMATOSIS; MIDDLE AGED; PROGNOSIS; PROTEIN KINASE INHIBITORS; RETROSPECTIVE STUDIES; SURVIVAL;

EID: 84897984741     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2013.12.009     Document Type: Article

References (21)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer statistics, 2013 CA Cancer J Clin 63 2013 11 30
2. A.M. Chen, T.M. Jahan, D.M. Jablons, J. Garcia, and D.A. Larson Risk of cerebral metastases and neurological death after pathological complete response to neoadjuvant therapy for locally advanced non-small-cell lung cancer: clinical implications for the subsequent management of the brain Cancer 109 2007 1668 1675 (Pubitemid 46595704)
3. A.F. Eichler, K.T. Kahle, and D.L. Wang et al. EGFR mutation status and survival after diagnosis of brain metastasis in non-small cell lung cancer Neuro Oncol 12 2010 1193 1199
4. Morris PG, Reiner AS, Szenberg OR, et al. Leptomeningeal metastasis from non-small cell lung cancer: survival and the impact of whole brain radiotherapy [published online November 15, 2011]. J Thorac Oncol.
5. J.H. Park, Y.J. Kim, and J.O. Lee et al. Clinical outcomes of leptomeningeal metastasis in patients with non-small cell lung cancer in the modern chemotherapy era Lung Cancer 76 2012 387 392
6. G.V. Scagliotti, P. Parikh, and J. von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
7. T. Ciuleanu, T. Brodowicz, and C. Zielinski et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
8. A. Bearz, I. Garassino, and M. Tiseo et al. Activity of pemetrexed on brain metastases from non-small cell lung cancer Lung Cancer 68 2010 264 268
9. F. Barlesi, R. Gervais, and H. Lena et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01) Ann Oncol 22 2011 2466 2470
10. T.S. Mok, Y.L. Wu, and S. Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
11. R. Rosell, E. Carcereny, and R. Gervais et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
12. C. Grommes, G.R. Oxnard, and M.G. Kris et al. "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer Neuro Oncol 13 2011 1364 1369
13. J.L. Clarke, W. Pao, N. Wu, V.A. Miller, and A.B. Lassman High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer J Neurooncol 99 2010 283 286
14. A. Sandler, R. Gray, and M.C. Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
15. M.A. Socinski, C.J. Langer, and J.E. Huang et al. Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases J Clin Oncol 27 2009 5255 5261
16. V.A. Levin, L. Bidaut, and P. Hou et al. Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system Int J Radiat Oncol Biol Phys 79 2011 1487 1495
17. B. George, W.J. Wirostko, T.B. Connor, and N.W. Choong Complete and durable response of choroid metastasis from non-small cell lung cancer with systemic bevacizumab and chemotherapy J Thorac Oncol 4 2009 661 662
18. T.N. Kreisl, L. Kim, and K. Moore et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
19. Besse B, Le Moulec S, Senellart H, et al. Phase II study of bevacizumab in combination with first-line chemotherapy or second-line erlotinib in non-squamous NSCLC patients with asymptomatic untreated brain metastases. Presented at: European Society for Medical Oncology 2012 Congress (ESMO 2012); September 28 to October 2, 2012; Vienna, Austria. Abstract 873.
20. Welsh JW, Komaki R, Amini A, et al. Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer [published online January 22, 2013]. J Clin Oncol.
21. Lee Y, Han JY, Kim HT, et al. Impact of EGFR tyrosine kinase inhibitors versus chemotherapy on the development of leptomeningeal metastasis in never smokers with advanced adenocarcinoma of the lung [published online July 6, 2013]. J Neurooncol.